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Abstract
Botulinum neurotoxin B (BoNT-B) mediates proteolytic cleavage of VAMP I/II (synaptobrevins I/II), which prevents vesicle-
membrane fusion and blocks neurotransmitter release. In the present study, we investigated the effects of BoNT-B on
neurotransmitter release in vivo from spinal primary afferent sensory fibers and the effects of this blockade on nociception.
With intrathecally (IT) delivered BoNT-B in C57B/l6 mice, we characterized the effects of such block on the release of
substance P (SP) from spinal afferent nociceptors (as measured by neurokinin-1 receptor, NK1-R, internalization), spinal
neuronal activation (as indicated by spinal C-Fos expression) and nociceptive behavior after intraplantar (IPLT) formalin. In
addition, we investigated the effect of IT BoNT-B on spinal nerve ligation-induced tactile allodynia. A single percutaneous IT
injection of BoNT-B 0.5 U at 2 or 5 days prior to IPLT formalin reduced NK1-R internalization and C-Fos expression. These
effects correlated with BoNT-B cleavage of VAMPI/II protein in tissue lysate. IT BoNT-B also produced a corresponding
reduction in phase 2 of formalin-evoked flinching behavior for over 30 days after IT injection. In mice with spinal nerve
ligation (SNL), tactile allodynia was observed, which was attenuated by IT BoNT-B 0.5 U over the next 15 days, as compared
to vehicle animals. These effects were observed without effects upon motor function. The specificity of the IT BoNT-B effect
is indicated by: i) IT co-injection of BoNT-B and anti-BoNTB antibody prevented effects on SP release, and ii) IT BoNT-B 50 U
in the Sprague Dawley rats showed no effect on formalin-evoked flinching or SNL-induced tactile allodynia, which is
consistent with rat resistance to BoNT-B. IT BoNT-B blocks transmitter release from spinal primary afferents, and attenuates
inflammatory nociceptive response and spinal nerve injury-induced neuropathic pain, in the absence of motor impairment.
These observations provide an initial assessment of the ability of IT BoNT-B to regulate spinal nociceptive processing.
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Introduction
Botulinum neurotoxins (BoNTs) are metalloproteases produced
by Clostridium botulinum. They mediate proteolytic cleavage of
protein subunits in the family of soluble N-methylaleimide-
sensitive attachment protein receptor (SNARE) proteins in the
synaptic terminal. There are seven BoNT serotypes (A–G). Each
neurotoxin serotype specifically and non-competitively cleaves one
site of a member of the SNARE protein complex: botulinum
neurotoxin serotype A (BoNT-A) cleaves SNAP-25. Botulinum
neurotoxin serotype C (BoNT-C) cleaves syntaxin. Botulinum
neurotoxin serotypes B, F, and G cleave VAMP/synaptobrevin
protein [1]. Such enzymatic cleavage results in inhibition of
vesicle-membrane fusion and prevents the release of neurotrans-
mitters. Previous studies have shown effects of BoNTs on
acetylcholine release from motor neurons and effects on muscle.
SNARE proteins, however, play a ubiquitous role in vesicle-
membrane fusion during neurotransmitter release in both the
peripheral and central nervous systems. Several studies have
demonstrated that treatment of neuronal systems and cell cultures
that BoNT-A inhibits release of acetylcholine, substance P [2],
glutamate [3], and calcitonin gene-related peptide [4,5]. Despite
the widespread role of SNARE proteins in CNS and PNS, there
has been little work on the effects of BoNTs on neurotransmitter
release in systems other than neuromuscular junction. Further-
more, the majority of this work has focused on ex vivo systems and
the effects on behavior have been described in a limited fashion.
Accordingly, in this series of studies, we examined the effects of
the intrathecal (IT) delivery of BoNT-B on substance-P (SP)
release from spinal primary afferent C-fibers in the spinal cord in
vivo upon stimulation by intraplantar (IPLT) formalin in the hind
paw. SP-specific binding to neurokinin-1 receptors (NK1-R) in the
superficial spinal dorsal horn, where C-fibers terminate, induces
NK1-R internalization which can be visualized immunohisto-
chemically as a quantitative assay for neurotransmitter release. IT
BoNT-B effects on post-synaptic activation was also demonstrated
by spinal C-Fos protein expression. In order to demonstrate the
functional significance of BoNT-B effects, we examined its effects
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ligation-induced tactile allodynia. These studies revealed a robust
effect of IT BoNT-B on neurotransmitter release and spinal C-Fos
expression, which correlated with suppression of formalin-evoked
pain behavior and nerve injury-induced hyperalgesia. The
specificity of this effect is supported by the observation that
intrathecal BoNT-B failed to have any effect after delivery in rats,
a finding consistent with a single amino acid variation in rat
VAMPI protein rendering resistance to BoNT-B cleavaging
activity.
Methods
Ethics Statement
All studies undertaken in this study were carried out according
to protocols approved by the Institutional Animal Care and Use
Committee of the University of California, San Diego.
Animals
Adult male C57B/l6 mice and Sprague Dawley rats (Harlan
Sprague Dawley Inc., Indianapolis, IN). Animals were housed in
vivarium minimum of 2 days before use, maintained on a 12/
12 hour day-night cycle, and are given food and water ad libitum.
Drug Delivery
Mouse intrathecal injections. Animals were anesthetized
using 5% isoflurane for induction and 3% isoflurane during the IT
injection. A 30G needle was inserted into the intrathecal space at
L5–L6, and a tail flick was observed as indication of correct
placement of the injection. Drugs were delivered using a Hamilton
syringe. Intrathecal injections of NaCl 0.9% or drug were given in
volumes of 5 mL for each dose given, unless otherwise stated.
Rat intrathecal injections. While anesthetized using 5%
isoflurane, rats were prepared with lumbar intrathecal (IT)
catheters as previously described [6,7]. After 5–7 days recovery,
rats were entered into the study to receive drug in volume of
10 mL, unless otherwise stated. Each injection is followed by 10 mL
of saline flush.
Drugs
Botulinum neurotoxin B (BoNT-B; MyoblocH, Solstice Neuro-
sciences Inc., South San Francisco, CA) was provided in solution
containing 5000 U/mL. BoNT-B was diluted in NaCl 0.9% such
that the dose to be delivered was present in a volume of 5 mL for
mouse studies and 10 mL for rat studies, unless otherwise stated. In
both rat and mouse studies, intraplantar formalin (5%, 20 mL) was
given in the left hind paw. For IT injections of BoNT-B titer,
BoNT-B was incubated with anti-BoNT-B antibody (rabbit
polyclonal; Abcam Inc., San Francisco, CA) at effective binding
concentrations determined in titer assay for 1 hour at 37uC prior
to IT injection.
Morbidity and Motor Function
Morbidity. Mice received intrathecal injection of BoNT-B at
doses 0.1 U–50 U. Clinical observations were made for
indications of toxicity: piloerection, labored breathing, normal
grooming behavior, normal ambulation, and exploratory
behavior. In order to assess weight loss, mice that received
maximal tolerable dose of BoNT-B were weighed 7 days after
intrathecal injection.
Grip strength. Five days after receiving IT NaCl 0.9% or
BoNT-B 0.5 U, animals were placed on top of a wire mesh
mounted on a scale. The experimenter lifts the animal from the
wire mesh by the tail. The grip strength is recorded as the maximal
force at the point of release from the wire mesh by the hind paws.
Motor function. Animals were required to remain suspended
underneath a wire mesh for up to 1 minute. When placed upside-
down under the wire mesh, animals were required to grip onto the
wire grid with front and hind paws, and grip strength is required to
support their body weight. Normal exploratory movement while
suspended underneath the wire mesh was also observed, as
indication of exploratory behavior and motor coordination.
Nociception
Formalin-Induced Flinching. A metal band was placed on
the left hind paw of the mouse and acclimated in the behavior
testing chamber at least 1 hour prior to formalin injection.
Intraplantar (IPLT) injection of formalin (5%, 20 mL) was
administered in the marked hind paw and the animal was
immediately returned to the detection device. Flinching behavior
was collected using an automated system for 40 minutes following
IPLT formalin injection [8].
Spinal Nerve Ligation (SNL). Same spinal nerve ligation
procedure was used for rats and mice following procedures
described in Kim and Chung, 1992 [9]. Animals were
anesthetized using xylazine (10 mg/kg) and ketamine (100 mg/
kg) cocktail and 3% isoflurane during ligation surgery. The L6
transverse process is removed to expose the L5 and L6 nerve roots.
A 6-0 silk suture is tied on the L5 spinal nerve distal to the spinal
cord. Animals were given 1 mL lactated Ringer’s solution with
carprofen subcutaneously immediately after surgery. At 5–7 days
after ligation surgery, increase in tactile hypersensitivity was
observed (tactile allodynia).
Tactile Allodynia Assessment. Animals were allowed to
acclimate in clear plastic testing chambers on wire mesh for at least
1 hour prior to testing. To assess paw withdrawal threshold
(PWT), von Frey filaments (Touch TestH Sensory Evaluators) were
applied to the left hind paw which is ipsilateral to the site of spinal
nerve ligation. Using the up-down method of von Frey filament
application [10], six readings were taken for statistical analysis of
tactile threshold.
Spinal Cord Harvest
For NK1-R internalization and spinal C-Fos expression studies,
animals were sacrificed at 10 minutes and 2 hours, respectively,
after IPLT formalin using intraperitoneal (IP) Euthosol (200 mL).
Animals were intracardially perfused with 0.9% NaCl, and fixed
using 4% paraformaldehyde. Laminectomy was performed to
extract the spinal cord. Harvested spinal cords were incubated for
24 hours in 4% paraformaldehyde, followed by 20% sucrose and
30% sucrose. For Western blot assays for VAMP I/II cleavage,
animals were anesthetized using 5% isofluorane and sacrificed by
decapitation. Spinal cord was harvested by hydroextrusion. Spinal
cord was placed in lysis buffer (0.5% Triton X-100, 50 mM Tris,
150 mM NaCl, and nanopure H2O), with protease and phospha-
tase inhibitors (Sigma Aldrich Co., St. Louis, MO), and
homogenized by sonication.
Immunohistochemistry
Tissue preparation. For NK1-R internalization studies,
lumbar tissue samples of L2–L5 incubated in rabbit anti-NK1-
R (Advanced Targeting Systems) and mouse anti-NeuN
(Chemicon) antibodies; followed by 2u Antibodies Fluroscein
(FITC)-conjugated AffiniPure F(ab)2 Fragment Donkey Anti-
Rabbit IgG and Rhodamine Red
TM-X-conjugated AffiniPure
Donkey Anit-Mouse IgG (JacksonImmuno Research). For C-Fos
expression studies, lumbar tissue samples of L2–L5 were
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anti-NeuN (Chemicon) primary antibodies. Tissue was then
incubated in fluorescent conjugated 2u antibodies: Streptavidin-
AlexaFluorH 555 conjugate and AlexaFluorH 488 goat anti-rabbit
IgG (Molecular Probes).
Tissue analysis. Dorsal horn regions of antibody-stained
spinal cord tissue were scanned using confocal microscopy (Leica
TCS SP5) 636 oil immersion objective. Images were viewed on
Adobe Photoshop CS2H. NK1-R internalization is characterized
based on a set of criteria: i) formation of an outline of NK1-R
immunoreactivity around NeuN immunoreactivity, ii) distortion of
NK1-R outline and appearance of endosomes indicative of NK1-
R internalization. The total number of NK1-R immunoreactive
neurons, with and without NK1-R internalization, was counted
and used to calculate percentage of cells showing NK1-R
internalization. Counting was performed without knowledge of
treatment.
Stastistical Analysis
Statistical analysis was performed on GraphPad Prism (Graph-
Pad Software, Inc.) using two-way ANOVA parametric analsysis.
Results are expressed as means 6 SEM. P,0.05 was taken as the
level of significance, unless otherwise stated. All behavioral data
are presented as the mean 6 SEM of the respective data set
plotted versus time. For Western blot quantification, blot was
developed on film and photo scanned. Band intensity was
analyzed usin ImageQuant TL software (GE Lifesciences Inc.).
All behavioral data are presented as the mean 6SE of the
respective data set plotted versus time. For the formalin model, the
area under the curve (flinch count vs. time) was calculated for
phase 1 (0–10 minutes) and phase 2 (11–40 minutes). For the
tactile allodynia data in the nerve injury model, paw withdrawal
thresholds (PWT) were plotted as percent of the pre-BoNT-B
treatment baseline PWT for each animal to reduce variations
between animals in the analysis. The effect-over-time curves for
each group was calculated and presented in the tactile allodynia
data accordingly.
Results
Dose tolerability of BoNT-B in the mouse
In order to determine a maximal tolerable dose of intrathecally
delivered BoNT-B in the mouse, animals received intrathecal (IT)
injection of BoNT-B, were observed for clinical indications of
toxicity and were tested for motor impairment and grip strength.
At doses 1 U–50 U given intrathecally, onset of motor disability
was observed within 24 hours after the injection. Because of
evident motor impairment and clinical indications of toxicity,
animals required sacrifice. The maximal tolerable dose was
determined to be 0.5 U, with survival and normal motor function
observed at 7 days after IT injection (table 1). The same animals
showed similar grip strength of the hind paw, as compared to IT
NaCl animals at 5 days after IT injection (figure 1A). The same
animals were required to hang underneath a wire mesh for up to
1 minute. Animals that received the maximal tolerable dose of
BoNT-B showed normal motor coordination, grip strength and
exploratory behavior on the wire mesh. Both NaCl and BoNT-B
treated animals remained suspended upside down underneath the
wire mesh for the required time (data not shown). In addition,
weight loss was monitored as one clinical indication for toxicity.
Animals that received BoNT-B 0.5 U also did not show significant
weight loss at 7 days after intrathecal injection, as compared to IT
saline pre-treated animals (figure 1B). IT BoNT-B 0.5 U was
established as the maximal tolerable dose for experiments from
this point forward.
BoNT-B cleavage of spinal VAMP I/II
In order to determine the cleavage of spinal VAMP I/II by
active BoNT-B, spinal cord tissue lysate was incubated with
BoNT-B. Western blot of control spinal cord tissue lysate shows
both VAMP I (19 kDa) and VAMP II (17 kDa) proteins. Tissue
lysate incubated with BoNT-B show significant decrease in VAMP
I/II whole protein (figure 2). VAMP I/II cleavage product of
smaller molecular weight was not observed, most likely due to
rapid enzymatic degradation.
Table 1. Morbidity after IT BoNT-B injection.
BoNT-B Doses Route Survival (days) N Clinical Obs*
50 U/10 uL IT 1 3 moribund
5 U/5 uL IT 1 2 moribund
1 U/5 uL IT 1 2 motor impairment
0.5 U/5 uL IT .2 2 normal
0.1 U/5 uL IT .2 2 normal
0.5 U/5 uL IT .7 4 normal
0.1 U/5 uL IT .7 4 normal
Table shows summary of clinical observations following intrathecal injection of
BoNT-B in mouse. Maximal tolerable dose was determined to be BoNT-B
0.5 U/5 mL.
*Clinical observation was made at time of sacrifice.
doi:10.1371/journal.pone.0019126.t001
Figure 1. BoNT-B effect on motor function and toxicity in the
mouse. A) Grip strength of mice that received IT NaCl (vehicle, n=5) or
IT BoNTB 0.5 U (n=5) 5 days prior to measurement on top of a wire
mesh mounted on a weigh scale. Grip strength was recorded as the
maximum force at the point of release from the wire mesh.
B) Histogram shows change in body weight of mice that received IT
NaCl (vehicle, n=4) and IT BoNTB 0.5 U (n=6) measured 7 days after IT
injection. Bars represent mean 6 SD.
doi:10.1371/journal.pone.0019126.g001
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Substance P specifically binds to neurokinin-1 receptors (NK1-
R) in the superficial dorsal horn (laminae I and II), causing
receptor internalization. Quantification of NK1-R internalization
in the superficial dorsal horn was used as an assay for
neurotransmitter release. To quantify NK1-R internalization, we
first standardized characterization of NK1-R expression and
internalization at high magnification (636). In confocal images of
lumbar tissue stained for NeuN and NK1-R immunoreactivity
(figure 3B–G), NK1-R expression is characterized by appearance
of an outline of NK1-R immunoreactivity surrounding NeuN
immunoreactivity. NK1-R internalization is characterized by
distortion of the NK1-R outline and appearance of endosomes.
This indicates migration of NK1-R immunoreactivity as receptors
undergo internalization. Confocal images of mouse lumbar dorsal
horns are counted for NK1-R expression and internalization at
high magnification based on these criteria. In animal that received
IT NaCl prior to IPLT formalin, ipsilateral dorsal horn showed
significantly elevated NK1-R internalization, as compared to
contralateral dorsal horn to the site of formalin injection
(Figure 3A).
We then characterized NK1-R expression in the superficial
dorsal horn rostrocaudally along the lumbar segment. Confocal
images from L1–L5 show statistically similar numbers of neurons
positive for NeuN immunoreactivity and NK-R expression
(approximately 30%) in the superficial dorsal horn (figure 3H).
We next examined lumbar segments L1–L5 for maximal formalin-
induced NK1-R internalization. Naı ¨ve, unstimulated mice showed
minimal (approximately 20–30%) basal NK1-R internalization in
the left and right dorsal horns. This was established as constitutive
NK1-R internalization in the absence of stimulation. Represen-
tative confocal images from animals that received IPLT formalin
show increasing NK1-R internalization from L1 through L5.
NK1-R internalization in the ipsilateral dorsal horn was maximal
in L4–L5 at 10 minutes after formalin injection (figure 3I). In
subsequent studies of formalin-evoked NK1-R internalization,
representative confocal images from L4–L5 were counted for
NK1-R expression and NK1-R internalization.
Effects of IT BoNT-B on formalin-evoked neurotransmitter
release
The effects of spinal BoNT-B on primary afferent substance-P
release from C-fibers were characterized by examining the effects
of intrathecally delivered BoNT-B on the release of SP evoked by
the unilateral intraplantar delivery of formalin. Animals received
IT NaCl or BoNT-B (0.1 U–0.5 U), at intervals prior to IPLT
formalin in the left hind paw. In animals that received intrathecal
(IT) NaCl pretreatment, dorsal horn ipsilateral to the site of
formalin injection shows marked increase in NK1-R internaliza-
tion, approximately 53%, as compared to the contralateral
unstimulated dorsal horn, approximately 25% (figure 4A). In
contrast, animals that received IT BoNT-B 0.5 U pretreatment
showed a marked reduction in the incidence of formalin-evoked
NK1-R interanlization in the ipsilateral dorsal horn (approxi-
mately 25%) as compared to the ipsilateral dorsal horn of a vehicle
animal (figure 4B–C). NK1-R internalization in the contralateral
dorsal horns of IT BoNT-B and NaCl pretreated animals did not
show any difference after IPLT formalin. Two-day and 5-day IT
BoNT-B pretreatment showed comparable reduction in NK1-R
internalization (figure 4D), which suggests a sustained effect of
BoNT-B on primary afferent neurotransmitter release. In separate
groups of animals, NK1-R internalization at 15 days and 30 days
after IT treatment was comparable to IT NaCl pretreated animals,
indicating recovery from IT BoNT-B effects on neurotransmitter
release between 5 days and 15 days after IT treatment.
Based on IT BoNT-B effects on formalin-evoked neurotrans-
mitter release from primary afferent sensory neurons, we next
investigated whether IT BoNT-B pre-treatment would result in
suppression of non-afferent neuron activation after IPLT formalin.
C-Fos protein expression, which is an immediate early gene
expressed upon neuronal activation, is used in our study as a
marker for central neuronal activation. Confocal images of spinal
cord tissue showed C-Fos protein activation in the spinal dorsal
horn, characterized by co-localization of C-Fos immunoreactivity
and NeuN immunoreactivity (figure 5A–C). At 2 hours after IPLT
injection, formalin induced elevated C-Fos protein expression in
the ipsilateral dorsal horn in vehicle animals that received IT NaCl
Figure 2. BoNT-B cleavage of spinal VAMP I/II. A) Immunoblots show VAMP I/II protein of control lumbar spinal cord tissue lysate and tissue
lysate incubated with BoNT-B (1:10 concentration). VAMP I and II bands are confirmed by VAMP I (19 kDa) and VAMP II (17 kDa) synthetic peptides.
B) Quantification of band intensity for control and BoNTB treated tissue VAMP I and II compared to b-Tubulin.
doi:10.1371/journal.pone.0019126.g002
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uniformly counted for expression and internalization after IPLT formalin injection. A) Representative confocal image of mouse dorsal horns ipsilateral
and contralateral to the site of formalin injection showing location of NK1-R positive cells (with, yellow circles; without, green arrows) internalization.
B–D) Examples of neuron in the dorsal horn showing expression of neurokinin-1 receptors. NK1-R expression is characterized by co-localization of
NeuN and NK1-R immunoreactivity. Merged image shows outlined of NK1-R on the membrane. E–G) Neuron showing NK1-R internalization,
characterized by co-localization of NeuN and NK1-R, as well as distortion of membrane outline marked by NK1-R immunoreactivity and formation of
endosomes indicative of receptor internalization. H) Graph showing number of neurons showing NK1-R expression in spinal dorsal horn along the
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received IT BoNT-B 0.1 U and 0.5 U 2-day pretreatment showed
marked decrease in formalin-evoked C-Fos expression in the
ipsilateral dorsal horn (figure 5E–F), as compared to vehicle
animals. This reduction in formalin-induced C-Fos expression was
maintained up to 30 days following IT BoNT-B treatment
(figure 5G). Confocal images of the unstimulated contralateral
dorsal horn did not show statistical difference in C-Fos expression
between treatment groups. The data suggest that IT BoNT-B pre-
treatment, which blocked neurotransmitter release from primary
afferent C-fibers, also reduced activation of superficial dorsal horn
interneurons upon stimulation by a painful chemical stimulus.
Effects of IT BoNT-B on formalin-induced nocifensive
behavior
To determine whether the effects of IT BoNT-B on primary
afferents fibers at doses which block neurotransmitter release and
C-Fos activation alter nocifensive behavior, the effects of IT
BoNT-B on formalin-induced flinching response was examined.
Mice received IT NaCl or IT BoNT-B 0.1 U–0.5 U pretreat-
ment 2 days prior to formalin-evoked flinching measurements.
IPLT formalin evoked robust biphasic flinching behavior in mice
that received IT NaCl pretreatment. This flinching behavior
showed a typical time course, suggestive of biphasic response (e.g.
phase I: 0–10 minutes and phase II: 11–40 minutes). Mice that
received IT BoNT-B 0.5 U 2-day pretreatment showed signifi-
cant reduction in phase II, but not phase I, of formalin-evoked
flinching response, as compared to vehicle animals (figure 6A).
Reduction of phase II formalin-evoked flinching behavior was
observed in different groups of animals that received IT BoNT-B
5 days, 15 days, and 30 days prior to IPLT formalin (figure 6B).
The data indicate that IT BoNT-B pretreatment reduces
chemically induced nocifensive behavior in the mouse, and that
this reduction in nocifensive behavior is sustained for up to 30
days after a single IT injection.
Effects of IT BoNT-B on neuropathic pain
Spinal nerve injury induces long-term neuropathic hyperalgesia
characterized by long-term tactile allodynia or decreased paw
withdrawal threshold (PWT) when stimulated by a normally
innocuous mechanical stimulus. Mice that received spinal nerve
ligation (SNL) of the L5 spinal nerve show significant decrease in
paw withdrawal threshold in response to von Frey filaments, as
compared to naı ¨ve non-ligated animals by 14–15 days after
ligation surgery. Immediately following baseline withdrawal
threshold measurements, single IT NaCl or BoNT-B 0.1 U–
0.5 U was administered and withdrawal thresholds were assessed
up to 15 days after IT injection. Animals that received SNL and
IT NaCl maintained paw withdrawal threshold below 1 g for the
duration of assessment, with little change from baseline PWT. In
contrast, animals that received IT BoNT-B 0.5 U showed increase
from baseline PWT within 6 hours after IT treatment. These
animals also showed a statistically significant and persistent
increase (normalization) in PWT from baseline for the next 15
days after IT treatment (figure 7A–B). The data suggests long-term
sustained alleviation of hyperalgesia by IT BoNT-B, as well as
long-term dose-tolerability of BoNT-B in the mouse. Although
systematic assessments motor function were not undertaken, daily
observation of motor behavior revealed that these animals showed
normal motor function and symmetrical ambulation, and did not
show signs of motor weakness at any time point.
Antibody binding of BoNT-B and effect on primary
afferent neurotransmitter release
Blockade of substance P release from primary afferent C-fiber
by intrathecal delivery BoNT-B should required an enzymatically
active and mobile neurotoxin. We hypothesized that co-injection
of BoNT-B with anti-BoNTB antibody inhibits the effects on
neurotransmitter release shown in previous experiments. BoNTB-
antibody titer assay showed effective binding concentrations of
BoNTB and antibody, as assessed on NativePAGE. BoNT-B
concentrations equivalent to IT injection of 0.5 U/5 mL incubated
with anti-BoNTB antibody at 1:10 dilution, and IT BoNT-B 1 U/
5 mL incubated with antibody at 1:5 dilution (figure 8A) resulted in
different banding pattern on NativePAGE, as compared to BoNT-
B control and BoNT-B with lower antibody concentrations. This
suggests difference in protein migration due to difference in charge
and/or mass correlated with antibody binding. Mice received IT
BoNT-B 0.5 U and 1 U co-injected with antibody at respective
titer concentrations 2 days prior to IPLT formalin. Lumbar spinal
cord tissue was then analyzed for NK1-R internalization. No
statistical difference was shown in NK1-R internalization between
mice that received IT NaCl and animals that received IT BoNT-B
and antibody co-injection. However, mice that received IT BoNT-
B 0.5 U, without antibody, showed reduced NK1-R internaliza-
tion, as compare to IT NaCl pretreated animals (figure 8B). Thus,
incubation with anti-BoNT-B antibody most likely renders the
neurotoxin immobile and unable to be internalized across the
synaptic terminal membrane.
Control for target specificity: Resistance to IT BoNT-B in
the rat
An important question relates to the target specificity of the IT
B0NT-B effect. We have hypothesized that these effects of IT
BoNT-B in the mouse is the result of BoNT-B specific cleavage of
VAMP I/II. In the mouse and human, BoNT-B cleaves VAMP I
protein at amino acid residues Gln/76-Phe/77, which results in
inhibition of neurotransmitter release. However, rat BoNT-B
displays replacement of amino acid residue Val for Gln in VAMP I
protein at the cleavage site, rendering VAMP resistant to this
cleavage mechanisms [11,12]. Rats that received IT NaCl or
placebo showed typical biphasic flinching behavior evoked by
intraplantar formalin. Rats that received IT BoNT-B in doses of
50 U–100 U showed no evident effects upon motor behavior at
day 3 when behavior tests were performed and no effects distinct
from controls on formalin evoked flinching (figure 9A). In
addition, unlike the mouse, IT BoNT-B did not reduce the tactile
allodynia in rats after spinal nerve ligation (figure 9B), as compared
to allodynic rats that received IT NaCl or IT placebo. This data
strongly suggest that BoNT-B specific and active enzymatic
cleavage of VAMP I/II is required to produce effects of BoNT-
B on neurotransmitter release, nociception, and SNL-induced
hyperalgesia in the mouse.
Discussion
The present in vivo studies demonstrate for the first time that the
intrathecal delivery of BoNTB produces a prominent block of the
evoked release of substance P from small primary afferents and a
lumbar segment. NK1-R expression is shown to be consistent along the lumbar spinal cord. I) Graph shows NK1-R internalization along the lumbar
segment at 10 minutes after IPLT formalin in the left hind paw (all n=3). Bars represent mean 6 SEM; * and ** P value,0.5.
doi:10.1371/journal.pone.0019126.g003
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PLoS ONE | www.plosone.org 6 April 2011 | Volume 6 | Issue 4 | e19126Figure 4. IT BoNT-B on neurotransmitter release from spinal primary afferent C-fibers. A–C) Figure shows representative confocal images
of dorsal horns of IT BoNTB pretreated and vehicle animals. Mice received IT injections 5 days prior to IPLT formalin. Both the ipsilateral and
contralateral dorsal horns are counted for NK1-R expression (green arrows), and for NK1-R internalization (yellow circles). At 10 mins after IPLT
formalin IT NaCl pretreated animal shows significant increase in NK1-R internalization in the dorsal horn ipsilateral to the site of formalin injection. In
contrast, in the IT BoNTB 0.1 U (n=4) and BoNTB 0.5 U (n=4) pre-treated animal, ipsilateral formalin-induced NK1-R internalization is significantly
reduced, as compared to the vehicle animals (n=4). There was no significant difference in contralateral NK1-R internalization between the BoNTB
pretreated and vehicle animals. D) Percentage of NK1-R expressing neurons in the dorsal horn that show internalization after IPLT formalin. Ipsilateral
dorsal horn shows marked increase in NK1-R internalization in the vehicle animals (n=5, pooled) after IPLT formalin. Animals that received IT BoNTB
0.5 U pretreatment 2 days (n=5) and 5 days (n=4) prior to formalin showed marked reduction in NK1-R internalization after IPLT formalin in the hind
paw. At 15 days (n=3) and 30 days (n=3) after IT administration, BoNTB 0.5 U did not show significant effect on formalin-evoked NK1-R
internalization, as compared to vehicle animals. Both vehicle and BoNTB pre-treated animals showed similar NK1-R internalization in the contralateral
dorsal horn. Bars represent mean 6 SEM; * and ** P value,0.5.
doi:10.1371/journal.pone.0019126.g004
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PLoS ONE | www.plosone.org 7 April 2011 | Volume 6 | Issue 4 | e19126Figure 5. IT BoNT-B reduces IPLT formalin-evoked C-Fos activation. A–C) Co-localization of NeuN and C-Fos immunoreactivity indicating C-
Fos expression at 2 hrs after IPLT formalin. D–F) Confocal images representative of C-Fos expression after IPLT formalin. In animals that received IT
NaCl 2 days prior to formalin, IPLT formalin induced marked increase of C-Fos expression in ipsilateral dorsal horn interneurons. In contrast, mice that
received IT 2-day pretreatment of either BoNTB 0.1 U (n=4) or 0.5 U (n=5) showed significant reduction in C-Fos protein expression, as compared to
IT NaCl pretreated animals (n=5). G) Quantification of C-Fos protein expression in the superficial dorsal horn at 2 hours after IPLT formalin. In
different groups of animals, pretreatment of IT BoNTB 0.5 U 2 days (n=5), 5 days (n=3), 15 days (n=2), and 30 days (n=3) prior to IPLT formalin
show significant decrease in formalin-evoked C-Fos expression in the ipsilateral dorsal horn, as compared to vehicle animals (n=5). Bars represent
mean 6 SEM; P-value,0.5.
doi:10.1371/journal.pone.0019126.g005
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ization into spinal cells, its cleavage of VAMP I/II protein, and the
lack of BoNT-B effect in the rat with known BoNT-B resistance
suggest that intrathecally delivered BoNT-B exerts its effects on
neurotransmitter release in part through VAMP I/II cleavage in
sensory afferents. Issues pertinent to the interpretations of these
findings will be considered below.
Distribution of intrathecal drugs and the BoNT-B effect
profile
Rostrocaudal distribution of the injectate following intrathecal
delivery largely depends on volume of the injectate. Five
microliters used in this series of studies is the typical volume used
in the mouse. Intrathecal delivery of a drug is relatively restricted
to the location of injection. In preliminary studies, the intrathecal
injection of a blue dye produced distribution up through the mid-
thoracic level, which clearly covers spinal segments where primary
afferents from the hind paws terminate at the spinal cord. On the
other hand, only 3% of intrathecal injectate is found in the brain
10 minutes after intrathecal injection [13]. While this series of
studies showed that intrathecal delivery of BoNT-B blocked
neurotransmitter release from primary afferent C-fibers and
nociception, it is important to appreciate that these effects were
not accompanied by motor impairment. Maximal tolerable dose,
or LD50, for intracerebroventricular delivery of BoNT-A and
BoNT-B has been previously established to be 3.75–15 pg of toxin
per mouse of average body weight [14]. The maximal tolerable
intrathecal dose reported in our studies is 5 pg per mouse of
average body weight, which is within range of toxin concentrations
previously described.
We believe that the absence of intrathecal BoNT-B effect on
motor function at doses that block spinal neurotransmitter release
reflect the spinal localization of BoNT-B effects and lack of
penetration of the toxin into deep laminae. Synaptic terminals of
small peptidergic primary afferents in the mouse lie in the
superficial dorsal horn (laminae I and II), about 25 mm from the
surface. Motor neurons lie more deeply (50–100 m) in the ventral
horn. Penetration of the parenchyma after IT delivery depends on
concentration gradient, lipid partition coefficient for small
molecules, and molecular weight, with large molecules showing
a diffusion rate inversely proportional to molecular weight [15,16].
Figure 6. Effects of BoNT-B on formalin-evoked flinching behavior in the mouse. A) Time course of formalin-evoked flinching behavior
measured up to 40 mins after formalin. Mice received IT BoNTB 0.1 U (n=8) or 0.5 U (n=11) and IT NaCl (n=12) 2 days prior to IPLT formalin
injection. B) Cumulative number of flinches compared between phases. Different groups of mice received IPLT formalin 2 days, 5 days, 15 days, and
30 days after IT BoNTB 0.5 U. Animals that received IT BoNT-B showed reduction of phase 2 of flinching response, compared to NaCl-treated animals.
Bars represent mean 6 SEM; P-value,0.5.
doi:10.1371/journal.pone.0019126.g006
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intrathecal injection have shown that large molecules diffuse
poorly into the parenchyma [17]. Accordingly, superficial
localization of BoNT-B results in a relatively restricted distribution
of the toxin to the site of injection, which we believe accounts for
the potent effect on sensory function and absence of effect on
motor function after intrathecal delivery in the mouse at
antinociceptive doses. Motor effects were clearly evident after
higher doses, a finding that could be consistent with either systemic
redistribution or perhaps reuptake and retrograde transport [18].
Intrathecal BoNTB and substance P release
The principal finding in the present studies is the block of SP
release from small peptidergic primary afferents as defined by the
reduction in NK1-R internalization. While previous work has
shown that BoNT-A inhibits release of acetylcholine, substance P
[2], glutamate [3], and calcitonin gene-related peptide [4,5], we
believe these are the first studies to demonstrate an effect upon
BoNTB release on peptidergic afferent neurons and to demon-
strate this action in vivo in a defined neuraxial system. The linkage
between NK1-R internalization and afferent SP release is based on
several components. 1) There are three sources of SP in the dorsal
horn: primary afferents, bulbospinal projections and intrinsic
neurons to a lesser extent. Previous work has reported that
depletion of SP in bulbospinal pathway has no effect on NK1-R
internalization in the superficial dorsal horn, while depletion of
primary afferent SP with capsaicin prevents NK1-R internaliza-
tion otherwise evoked by a noxious stimulus [19]. 2) Intrathecal
morphine, which reduces extracellular spinal SP through a pre-
synaptic action of peptidergic terminals [20], reduces the fraction
of spinal neurons that show NK1-R internalization after
stimulation with a noxious stimulus. 3) In vitro studies using spinal
cord slices have demonstrated covariance between local SP
concentration and increase in spinal NK1-R internalization [21].
4) A variety of stimulus conditions in vivo known to initiate activity
in peptidergic fibers will increase NK1 internalization in the
ipsilateral dorsal horn present [19,22]. Importantly, while NK1-R
expression s consistent along the L1–L5 lumbar segments, NK1-R
internalization in the dorsal horn ipsilateral to the site of IPLT
formalin injection (and other treatments) is maximal in the
ipsilateral L4–L5 segments, consistent with the location of
terminals from sensory input originating from the ipsilateral hind
paw. Based on these observations, spinal NK1-R internalization is
a robust reflection of SP release from spinal primary afferents.
Role of VAMP cleavage
The mechanisms of action of BoNTs on neurotransmitter
release depend on toxin internalization into neurons and the
specific cleavage of synaptic proteins. Botulinum neurotoxin
structure consists of light chain (LC) - the protease domain
responsible for enzymatic cleavage of SNARE proteins, and heavy
chain (HC) whose receptor domain which mediates binding to
membrane receptor and translocation domain mediates toxin
translocation into neurons. Toxin internalization is mediated by
LC binding to ganglioside GT1b [23] and synaptotagmin I and II
which are transiently expressed on plasma membrane during
vesicle recycling [24], as well as contribution of the heavy chain as
a conduit for toxin internalization [25,26]. During neurotransmit-
ter release, Fusion of SNARE proteins syntaxin, synaptobrevin,
and SNAP-25, resulting in formation of a four-a-helix bundle –
the SNARE protein complex - is critical for vesicle fusion with the
plasma membrane and release of neurotransmitters [27]. Enzy-
matic cleavage of VAMP I/II by LC protease domain of BoNT-B
results in failure of formation of SNARE protein complex and
prevention of vesicle-membrane fusion during neurotransmitter
release.
In the present work, confirmation that BoNT-B effects were
indeed the result of VAMPI/II proteolytic cleavage is provided by
several experiments. 1) Incubation of tissue lysate with BoNT-B
demonstrated a decrease in VAMPI/II protein. 2) Co-injection of
BoNT-B with titrated concentrations of anti-BoNTB antibody
prevented the in vivo effects on formalin-induced NK1-R
internalization, in which case the antibody may have rendered
the toxin immobile or unable to be internalized into the cytoplasm.
3) Finally, rat resistance to BoNT-B serves as a biological negative
control. BoNT-B proteolytically cleaves VAMP I and II at amino
acid residues Gln/76-Phe/77 in mouse and human. In the rat
VAMP I protein, Gln/76 is replaced by a valine residue, which
Figure 7. Effects of IT BoNTB on neuropathic hyperalgesia. SNL-
induced tactile allodynia after IT BoNT-B. Paw withdrawal threshold
(PWT) was measured using von Frey filaments at 14–15 days after SNL
surgery and continued up to 15 days after IT injection. A) Time course of
tactile allodynia up to 15 days after IT treatment, expressed as %
change from baseline. At 14–15 days after SNL surgery, baseline PWT
was measured: naı ¨ve (n=8), 1.3560.53; NaCl, 0.6960.32; BoNTB 0.1 U,
0.5860.32; BoNTB 0.5 U, 0.4560.24. Mice received IT NaCl (n=8) or
BoNTB 0.1 U–0.5 U (n=6) immediately after baseline PWT was
measured at day 14–15 days after SNL (t=0). B) Area under curve of
% change from baseline PWT over 15 days after IT treatment. Bars
represent mean 6 SEM; * and ** P value,0.5.
doi:10.1371/journal.pone.0019126.g007
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specific VAMPI/II cleavage is required for BoNT-B effect on
formalin-evoked neurotransmitter release and nocifensive re-
sponse.
Recovery from BoNTs has been explored in motor neurons at
the neuromuscular junction and has been proposed to require de
novo protein synthesis and remodeling at the synapse [28]. Motor
neurons have been shown to produce sprouting of processes 32
days after denervation by BoNT-A treatment, where sprouts
contain SNARE proteins [29]. Sprouting occurs concurrently with
nerve-evoked muscle twitch at 28–30 days after BoNT-A
treatment [30]. In the present study, recovery from BoNT-B
effect on formalin-evoked C-Fos expression and on nociceptive
behavior through 30 days after BoNT-B treatment. This duration
is consistent with findings in previous studies using BoNTA
through systemic delivery. Based on the similar properties between
BoNT-A and BoNT-B, it is reasonable to believe that similar
mechanisms underlie recovery from intrathecal BoNT-B effects
shown in the present study.
Effects of Intrathecal BoNT-B on spinal nociceptive
processing
IT BoNTB, at doses having no effect upon motor function
produced persistent (as long as 30 days) and significant effects
Figure 8. Prevention of BoNT-B effects on primary afferent neurotransmitter release. Effective binding concentrations of BoNT-B and
antibody were determined by titer assay on NativePAGE. Co-injection of BoNT-B and anti-BoNTB antibody was administered in mice 2 days prior to
IPLT formalin, and spinal cord tissue was harvested at 10 minutes after formalin for analysis of NK1-R internalization. A) Immunoblot of BoNTB-
antibody titer assay. BoNT-B was incubated with anti-BoNTB antibody (Ab) at dilutions 1:1, 1:5 and 1:10. The effective binding concentrations were
determined to be BoNTB 0.5 U/5 mL incubated with anti-BoNTB antibody at 1:10 dilution, and BoNTB 1 U/5 mL incubated with antibody at 1:5
dilution. B) Histogram of NK1-R internalization in the ipsilateral dorsal horn in animals that received IT BoNTB-antibody titer (n=3), BoNTB 0.5 U–1 U
(n=3), and IT NaCl (n=4). Bars represent mean 6 SEM; P-value,0.05 significance.
doi:10.1371/journal.pone.0019126.g008
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reversed the tactile allodynia otherwise occurring after nerve
injury for at least 15 days. Importantly, the pharmacology of these
various behavioral states is distinct. The formalin model, the
biphasic flinching behavior is believed to reflect the acute afferent
excitation during the phase 1 and an ongoing low level of afferent
traffic during the phase 2 of the behavioral response which evokes
prominent flinching as a result of potent facilitated state initiated
by the high level of afferent input observed during phase 1 [31,32].
Nerve injury leads to a persistent tactile allodynia. Several
mechanisms are considered to underlie this facilitated state,
including dorsal horn reorganization, a loss of inhibitory control,
a corresponding increase in dorsal horn excitability [33,34] and
associated with an increase in spinal glutamate release [35].
Phase 2 flinching, but not phase 1 flinching, and post nerve
injury tactile allodynia are blocked by spinal NK1-R receptor
antagonists [36,37,38]. The failure to observe effects of NK1-R
blockade in nerve injury pain is consistent with the lack of
evoked release of SP by tactile stimulation in nerve injured
animals [39]. It should be stressed that other spinal transmitter
systems, notably those for glutamate released form primary
afferents and from dorsal horn excitatory interneurons, are
known to play a critical role in both phases of the formalin
model and the post nerve injury allodynia [40,41,42]. IT delivery
of AMPA antagonists will block phase 1 and phase 2 formalin as
well as tactile allodynia, whereas NMDA antagonists will reduce
phase 2 flinching only and nerve injury evoked tactile allodynia
[31,43,44]. Consistent with the ability of BoNTB to produce a
persistent block of excitatory drive in the spinal dorsal horn, we
noted that the increase in C-Fos expression following intraplan-
tar formalin [45] and was persistently blocked by IT BoNT-B at
doses which attenuated the evoked SP release and phase 2
formalin evoked flinching and the nerve injury evoked tactile
allodynia.
Figure 9. Absence of BoNT-B effect on pain in the rat. A)Time course (left panel) of observed flinching behavior and histogram of phasic
cumulative flinches (right panel) comparing phase I (0–10 mins), phase II (10–40 mins), phase IIA (10–20 mins) and phase IIB (20–40 mins). Rats
received IT BoNTB (50 U, 10 mL; 100 U, 20 mL; n=3) 3 days prior to IPLT formalin, as compared to placebo (10 mL; n=3) and NaCl (10 mL; n=3)
pretreated animals. B) Spinal nerve ligation of the L5 spinal nerve was performed in rats 7–10 days prior to IT injection. On day 0, rats received IT
BoNT-B (100 U,20 mL; n=4), saline (n=2), or placebo (n=2). Paw withdrawal threshold in response to von Frey filaments was measured each day for
3 days following IT injections. Bars represent mean 6 SEM.
doi:10.1371/journal.pone.0019126.g009
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believe that functional profile outlined above reflects on a more
complicated action. As noted, if the effects of IT BoNT B were
uniformly expressed on all releasing functions of the peptidergic
neurons, then we would expect that there would be a potent effect
upon the release of other transmitters, notably glutamate. Had
glutamate release from small afferents been blocked, we would
expect to see a loss of phase 1 flinching, which was not observed.
Moreover, if block of the afferent SP release were the only point of
interaction, we would expect that the recovery from BoNT-B
effects on all measures to be comparable. As noted, SP release
recovered between 5 and 15 days post injection, whereas the block
of the formalin-evoked flinching was comparable to the continued
suppression of C-Fos, persisted for 30 days. Similarly, the
pharmacology of the anti-allodynic effect in nerve injury suggests
a role for glutamate, but fails to support a role for SP. In any case,
the block of allodynia persisted robustly for at least 15 days,
beyond the time of recovery for the SP release block. We thus
conclude that the IT BoNT-B was exerting an effect not only on
SP release but on that of other spinal transmitters, notably
glutamate, and not only on primary afferent terminals, but those
perhaps from inter-neurons. Previous work has shown that BoNTs
block glutamate release from motor neurons and hippocampal
neurons [3]; these effects are also mediated by cleavage of SNARE
proteins [46]. It is important to emphasize that the observed
changes in sensory function after IT-BoNT-B did not generally
alter ambulation or normal function which would have occurred
had there been a promiscuous block of all large afferent
transmission (e.g. a phenomena commonly observed with various
ionotrophic glutamate receptor antagonists). An additional
possibility is suggested by the observation that BoNT-B can
inhibit long term potentiation (LTP) in hippocampal CA1
pyramidal cells without blocking baseline synaptic responses
[47,48]. LTP is considered to have mechanistic similarities to
spinal facilitated states as manifested in the formalin model.
Failure to see an effect upon baseline responses in hippocampal
systems parallels our observation that IT BoNT-B had no effect
upon phase 1 formalin or acute nociception, but diminished the
facilitated state. Of interest, the effects of BoNT-B on LTP were
believed to be associated with a suppression of trafficking of
AMPA receptors into the membrane [48]. It will be interesting to
determine whether a similar phenomenon applies to the present
observations with intrathecal BoNT-B.
In summary, the present studies emphasize the potent effect of
BoNT-B on the in vivo release from a well-defined pool of
peptidergic primary afferents. In addition, given the differential
pharmacology and recovery intervals for the several effects
examined, we believe these studies emphasize the likely effects
on the release of other spinal transmitters and upon non-afferent
terminals. It also raises the question as to the potential differential
effects exerted by BoNT serotypes and their derivatives.
Importantly, the in vivo model allows definition of the behavioral
consequence of the spinal drug action and permits demonstration
of an effective therapeutic rationale which likely reflects the access
of the intrathecal drug to deeper neurons. These studies thus
suggest a potential therapeutic direction for a persistent single dose
regulation of spinal nociceptive processing. It should be empha-
sized that the use of such persistent agents into the human spinal
canal must be subject to extensive preclinical safety evaluation
[49,50].
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